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Abstract
Background and purpose: Wilson disease (WD) is an autoso-
mal recessive inherited disorder of hepatic copper metabolism.
Clinical manifestations of WD include neurologic, hepatic and
psychiatric symptoms. Most WD patients with the neuropsy-
chiatric form, and some with the hepatic and presymptomatic
forms have both hypointense and hyperintense lesions in basal
ganglia on T2-weighted magnetic resonance imaging (MRI),
which can be iron and copper accumulation. It has been estab-
lished that T2* and susceptibility-weighted imaging (SWI)
are highly sensitive in demonstrating brain iron accumulation,
showing decreased signal intensity. Hypointense globus pal-
lidus (GP) signal has been described on T2-, T2*-weighted
images and on SWI as typical MRI lesion for patients with
neurodegeneration with brain iron accumulation (NBIA). 
We investigated whether WD patients have MRI changes 
suggesting iron accumulation using T2*-weighted and
VEN_BOLD SWI imaging protocols.
Material and methods: Standard MRI with additional
sequences (T2*-weighted and VEN_BOLD SWI) was per-
formed in consecutively admitted, clinically stable, and treat-
ed patients.
Results: Twenty-eight patients entered the study. Hypointensi-
ty in the GP was observed on T2*-weighted images in 10 pa-
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St reszc zen ie
Wstêp i cel pracy: Choroba Wilsona jest genetycznie uwarun-
kowanym, dziedziczonym autosomalnie recesywnie scho rzeniem
powoduj¹cym upoœledzenie metabolizmu miedzi. Wyró¿nia siê
nastêpuj¹ce postacie kliniczne: neurologiczn¹, psychiatryczn¹ 
i w¹trobow¹. U wiêkszoœci pacjentów z postaci¹ neurologiczn¹
choroby Wilsona, a tak¿e u czêœci osób z postaci¹ w¹trobow¹
i bezobjawow¹ stwierdza siê hipointensywne i hiperintensywne
zmiany w j¹drach podkorowych w obrazach T2-zale¿nych rezo-
nansu magnetycznego (RM) mózgu, które mog¹ œwiadczyæ
o gromadzeniu zarówno miedzi, jak i ¿elaza. Wiadomo tak¿e,
¿e badanie RM w sekwencjach T2*-zale¿nej i VEN_BOLD
SWI (susceptibility-weighted imaging) pozwala z du¿¹ czu³oœci¹
wykrywaæ gromadzenie ¿elaza w tkance. Hipointensywny syg -
na³ ga³ki bladej w RM mózgu w obrazach T2*-zale¿nych
i w sekwencji VEN_BOLD SWI jest typowy dla neurodege-
neracji z gromadzeniem ¿elaza (neurodegeneration with brain iron
accumulation – NBIA). Celem niniejszej pracy by³o stwierdze-
nie, czy pacjenci z chorob¹ Wilsona maj¹ zmiany w RM mózgu
w sekwencjach T2*-zale¿nych i VEN_BOLD SWI sugeruj¹ce
gromadzenie ¿elaza.
Materia³ i metody: Badanie RM, standardowe oraz w sekwen-
cjach T2*-zale¿nych i VEN_BOLD SWI, zosta³o wykona-
ne u wszystkich kolejnych pacjentów przyjêtych do II Klini-
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Introduction
Wilson disease (WD) is an autosomal recessive in -
herited disorder of hepatic copper metabolism that is
caused by malfunction of a putative copper-transport-
ing P-type APTase (ATP7B). The cellular damage asso-
ciated with this disorder is thought to be due to copper
deposition in affected tissues, principally the liver and
brain [1]. Clinical manifestations of WD include neu-
rologic, hepatic and psychiatric symptoms.
Abnormal findings in magnetic resonance imaging
(MRI) – including brain atrophy; hyperintense lesions
on T2-weighted images in putamen, pons, midbrain,
and thalamus; and hypointense signals of basal ganglia
on T2-weighted images – are observed in most WD pa -
tients with the neuropsychiatric form, and in some pa -
tients with the hepatic and presymptomatic forms [2-7].
Simultaneous involvement of basal ganglia, thalamus
and brainstem seem to be pathognomonic for WD [8].
Of those abnormalities, the hyperintense T2 lesions are
believed to be gliosis or edema, whereas the hypointense
T2 lesions likely indicate ion accumulation [9]. MRI
T1-hyperintensity in the pallidum is also observed in
WD patients, probably due to manganese accumulation
in cases of liver failure [10].
Brain ion accumulation has recently become a topic
of great interest. The role of brain iron deposition in
normal aging and neurodegeneration has been recog-
nized. Iron deposition has been demonstrated within the
substantia nigra in Parkinson disease, and in structures
affected by β-amyloid plaques in Alzheimer disease
[11]. Iron is thought to play a role in the pathogenesis
of common neurodegenerative diseases, probably via
increased oxidative stress [12,13].
Since ions are paramagnetic, MRI techniques such
as T2*-weighted imaging and BOLD imaging seem to
be very sensitive tools for detecting in vivo ion accumu-
lation. It has been established that T2*-weighted images
are highly sensitive to brain iron accumulation [11],
which causes decreased signal intensity. T2* imaging
could also be highly sensitive to copper depositions [7].
Currently available MRI blood oxygenation level-de -
pendent (BOLD) techniques, like susceptibility-weight-
ed imaging (SWI; VEN_BOLD SWI), are useful for
vessel imaging, but seem to be more sensitive for detect-
ing ion deposits (especially iron) than conventional MRI
[14,15].
Hypointense signals of basal ganglia, primarily hypo -
intense globus pallidus, have been described on T2-
weighted images from WD patients similarly to the typi -
cal MRI changes of neurodegeneration with brain iron
accumulation (NBIA) [11]. Therefore, in this study we
aimed to observe the presence of MR changes typical
of NBIA in WD patients, using the standard T1- and




All WD patients admitted to our department bet -
ween March and August 2011 were subjected to MR
examination with an established protocol. This study
was approved by the Ethical Committee of the Institute
of Psychiatry and Neurology and written consent was
obtained from all subjects.
Wilson disease diagnosis was based on typical neuro-
logical and/or hepatic symptoms, biochemical markers
(decreased ceruloplasmin level, raised 24-hour urinary
copper concentration, and decreased plasma copper con-
centration), and genetic examination, as described previ-
ously [16]. A predominant symptom scoring system was
used to classify symptomatic patients, as described pre-
viously [17]. As the number of patients in the study was
small, we did not compare different clinical groups (hepa -
tients. Using the VEN_BOLD SWI technique, we found
hypointense signal in GP in 20 patients.
Conclusions: MRI data suggest not only copper but also iron
accumulation in GP in WD patients.
Key words:Wilson disease, magnetic resonance imaging, cop-
per, iron.
ki Neurologii w okresie obserwacji. Wszyscy pacjenci byli
w stabilnym stanie i leczono ich z powodu choroby Wilsona.
Wyniki: Do badania w³¹czono 28 pacjentów. Hipointensyw-
ne zmiany w ga³ce bladej w obrazach T2*-zale¿nych stwier-
dzono u 10 z nich. W sekwencji VEN_BOLD SWI zmia-
ny hipointensywne zaobserwowano u 20 osób.
Wnioski: Wyniki wskazuj¹ na gromadzenie nie tylko miedzi,
lecz tak¿e ¿elaza w ga³ce bladej u pacjentów z chorob¹ Wilsona.
S³owa kluczowe: choroba Wilsona, rezonans magnetyczny,
miedŸ, ¿elazo.
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tic vs. neurologic) as well as disease duration and kind 
of treatment (zinc sulfate vs. penicillamine). All patients
were on therapy and were clinically stable for at least 
6 months prior to the start of the study.
Imaging study
All images were acquired on a 1.5 T MRI unit
(Philips). T1-weighted (TR = 596 ms, TE = 15 ms)
and T2-weighted (TR = 6783 ms, TE = 140 ms)
images were taken in axial planes with 5-mm slice thick-
ness. Gradient echo T2*-weighted images were obtained
as a single-echo sequence (TR = 693 ms, TE = 23 ms;
flip angle = 20°). The VEN_BOLD SWI (TR = 
= 34 ms, TE = 49 ms) were performed for all patients.
Lenticular nucleus (putamen and globus pallidus) was
assessed. Other structures (putamen, pons, thalamus,
cerebellum, substantia nigra [SN], red nucleus [RN],
caudate and cortex) were also assessed, but this data is
not presented in this paper. The MRI were analyzed by
the neurologist blinded to the clinical examination.
Results
Twenty-eight patients (11 males) entered the study.
The mean age was 32 years (standard deviation [SD],
10). All subjects underwent the full MRI protocol.
Mean time from onset of symptoms to MRI study was
9.32 years (SD, 7.28). Clinical presentation and MR
changes are shown in Table 1.
No MRI abnormalities on T1- and T2-weighted
images were observed in 13 patients. One patient suffer-
ing from previously described liver failure exhibited
hyperintense changes in globus pallidus on T1-weighted
images. On T2-weighted images, 11 patients had only
hyperintense changes in putamen, 9 had hypo intense
changes in globus pallidus and 6 patients had both hyper-
intense changes in putamen and hypointense changes 
in globus pallidus. T2*-weighted images showed hypo -
intensity in the globus pallidus in 10 patients. Using the
VEN_BOLD SWI technique, we found hypointense
signals in globus pallidus in 20 patients (Fig. 1).
Discussion
The presence of basal ganglia iron deposition in neu-
rodegenerative diseases has been established; globus 
pallidus MR hypointensity on T2- and T2*-weighted
sequences is a typical abnormality for all NBIA [11].
Our study showed globus pallidus hypointensity on T2*-
weighted images in 10 patients and in VEN_BOLD
SWI in 20 patients. The exact nature of these observed
hypointense lesions is still unclear. Since copper is para-
magnetic, it is possible that copper shortens the T2 relax-
ation time and causes decrease of signal intensity [7],
but some authors believe that copper typically results in
increased T2 signal abnormalities [10]. Symmetric
hypointense lesions in basal ganglia have been described
despite long-term copper chelating therapy [7,15], while
high signal changes in T2-weighted images usually
improve or totally disappear under sufficient medical
treatment [7,18,19]. While the contribution of copper
to hypointense effects on T2*-weighted and BOLD
images has not yet been determined, the utility of 
these sequences in demonstrating iron deposition has 
been described [11,14]. Copper-iron interactions in
WD patients are logical, as ceruloplasmin is the major
ferro xidase and is essential for iron metabolism, and
acerulo plasminemia is related to a heavy iron load [20].
Liver biopsy has detected both iron and copper deposi-
tion in WD patients [20]. Our results suggest that
VEN_BOLD SWI imaging is more sensitive than T2-
weighted sequences for detecting globus pallidus inten-
sity changes in WD. The only published data about
Clinical presentation
Neurological Hepatic Presymptomatic
n = 9 n = 13 n = 6
No MRI changes 2 8 3
Lenticular nucleus hyperintensity in T2-weighted image 7 3 1
Lenticular nucleus hypointensity in T2-weighted image 6 0 3
Lenticular nucleus hypointensity in T2*-weighted image 7 0 3
Lenticular nucleus hypointensity in VEN_BOLD sequence 9 6 5
Table 1. Clinical presentation and magnetic resonance imaging (MRI) abnormalities in 28 examined patients
VEN_BOLD – blood oxygenation level dependent imaging venography
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SWI in WD patients is a case study in which paramag-
netic signals on SWI remained unchanged despite ther-
apy during a six-month follow-up [15].
Our study has number of limitations, including 
the small number of patients in each clinical group and
that MR imaging was performed at different time points
for each patient. Additionally, all patients were treated
with one of two different protocols, which might influ-
ence our results; long-term penicillamine treatment com-
pared to zinc sulfate seems to be responsible for more
severe hepatic iron accumulation [21].
Conclusions
We find interesting the idea that WD seems to involve
accumulation of not only copper but also iron. This
hypothesis is supported by the presence of hypointense
lesions on T2*-weighted images and SWI sequences that
are sensitive for iron depositions in patients under de-cop-
pering therapy. Further studies, including larger groups
of patients, and post-mortem studies are necessary.
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